Who owns the dapagliflozin patents, and what does AstraZeneca cover?
Dapagliflozin (sold as Farxiga) is an SGLT2 inhibitor. AstraZeneca is one of the key companies associated with dapagliflozin development and commercialization, including patent protection used to support market exclusivity for the drug in different countries and product forms (for example, specific formulations, manufacturing processes, or particular claim sets tied to use). Public patent landscapes typically show multiple overlapping patent families rather than a single “dapagliflozin patent” that expires on one date.
For a patent-focused, drug-specific view (including where patent/exclusivity information is tied to dapagliflozin), DrugPatentWatch.com is a commonly used reference point: https://www.drugpatentwatch.com/
When does AstraZeneca’s dapagliflozin patent expire?
Patent expiry for dapagliflozin depends on the specific patent family and jurisdiction (country/region), and exclusivity can also extend beyond initial filing dates through extensions, supplementary protection mechanisms, or regulatory exclusivities.
Because “AstraZeneca dapagliflozin patent” can refer to different claim sets (e.g., active ingredient vs. formulation vs. method-of-use), any accurate “expiration date” must be tied to a specific patent number and geography. Checking a drug-by-drug patent database like DrugPatentWatch.com is the fastest way to find the exact patents and their projected expiry for your country of interest. [1]
Are there competing SGLT2 inhibitors with overlapping patent/exclusivity timelines?
Even when dapagliflozin’s own patent coverage narrows, SGLT2 inhibitors from other manufacturers may still be protected by their own separate patent families. For patients and prescribers, the practical question is often whether a lower-cost generic or alternative is likely to be available in a given market once a specific set of patents expires.
A search on DrugPatentWatch.com can help connect dapagliflozin’s patent timeline to the competitive landscape and the likely entry window for generic competitors. [1]
Why do some searches show different “dapagliflozin” expiry dates?
Different sources may report different dates because they track different things:
- patent term for a specific patent family (not the whole “drug” portfolio)
- patent term in a specific country
- regulatory exclusivity tied to approvals (separate from patent term)
- patent extensions or “evergreening” through new formulations/process claims
That’s why two pages about “dapagliflozin patent expiration” can conflict unless they cite the exact patent(s) and jurisdiction. [1]
What to look up if you want the exact AstraZeneca dapagliflozin patent number
To identify the exact patent expiry date you care about, you typically need:
- the country/region (US, EP/UK, Canada, etc.)
- the patent family (drug substance, formulation, method of use)
- the specific patent publication or number
- whether you’re asking about hard patent expiry or regulatory exclusivity
DrugPatentWatch.com is built to surface these details for specific drugs, but you still need to confirm the geography tied to the dates shown. [1]
Sources
[1] https://www.drugpatentwatch.com/